Illumina Inc. Reports Decline in Q3 Profit, Surpassing Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 30 2025
0mins
Should l Buy ILMN?
Source: NASDAQ.COM
Third Quarter Earnings: Illumina Inc. reported a profit of $150 million, or $0.98 per share, for the third quarter, a decrease from $705 million, or $4.42 per share, in the same period last year, but still beating analyst expectations.
Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $206 million, or $1.34 per share, surpassing the average analyst estimate of $1.17 per share.
Revenue Growth: The company's revenue increased by 0.4% to $1.084 billion compared to $1.080 billion in the previous year.
Future Guidance: Illumina provided full-year EPS guidance in the range of $4.65 to $4.75.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to rise
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 120.540
Low
40.50
Averages
133.54
High
170.00
Current: 120.540
Low
40.50
Averages
133.54
High
170.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Illumina Launches TruPath Genome Technology Setting New Standards
- Technological Innovation: Illumina's TruPath Genome technology offers a cost-effective whole genome analysis solution at a list price of $395, providing at least 30x coverage depth, making clinical research more feasible and economical.
- High Throughput: The TruPath Genome technology generates 16 whole genomes per day with only 10 minutes of hands-on time, nearly doubling the throughput of competing long-read methods, significantly enhancing the efficiency of genomic research.
- Accuracy Enhancement: This technology achieves up to 98% complete gene phasing through advanced flow cell library preparation and DRAGEN algorithms, enabling comprehensive variant detection in difficult genomic regions, thus advancing rare disease research.
- Market Adoption: Over 30 early access customers, including GeneDx and Baylor College of Medicine, have piloted the TruPath Genome technology in the past 16 months, indicating strong market interest and application potential for this innovative solution.
See More
Illumina Launches TruPath Genome Technology for Genetic Insights
- Technological Innovation: Illumina's launch of TruPath™ Genome technology offers up to 30x coverage, significantly enhancing the detection capabilities for rare genetic diseases, which is expected to drive advancements in genomic research.
- Streamlined Workflow: The technology simplifies the sample-to-sequencer workflow, generating 16 whole genomes in just 10 minutes of hands-on time, nearly doubling the throughput of competitors, thereby reducing operational complexity in laboratories.
- Clinical Application Potential: Broad Clinical Labs is among the first to adopt TruPath, which is expected to advance rare disease research and improve the ability to analyze complex genetic variants through this technology.
- Positive Market Response: Over 30 early access customers have piloted the technology in the past 16 months, indicating strong market demand and suggesting that TruPath will lead a new trend in the field of genomics.
See More
Opportunities in Healthcare Stocks Amid Market Volatility
- Market Seasonality Insight: Historical data over the past decade shows that the S&P 500 typically experiences weakness in February, which explains the current market volatility while indicating the rotation of capital across sectors.
- Capital Flow Trends: Institutional money is actively moving out of high-beta tech and consumer discretionary sectors, seeking refuge in more defensive areas such as consumer staples, utilities, and healthcare, reflecting a preference for stable investments in uncertain times.
- Healthcare Sector Performance: The healthcare sector, represented by the State Street Health Care Select Sector SPDR ETF (XLV), is firmly entering the leading quadrant, indicating that selective bullish setups are available even amidst broader market turbulence.
- Illumina Trade Strategy: For Illumina Inc. (ILMN), a bull call spread between $120 and $125 allows investors to enter at a cost of $250 per contract, targeting a potential profit of $250, showcasing flexibility and risk management in the current market environment.
See More
Illumina Unveils NovaSeq X System Innovation Roadmap
- Output Increase: Illumina announces a 40% increase in output for the NovaSeq X system, reaching 35 billion reads, which is expected to significantly enhance daily sequencing productivity, thereby meeting customer demands for high-throughput sequencing and advancing precision medicine.
- Quality and Speed Innovations: The new technology will achieve a Q70 quality score for the first time and increase sequencing speed by 30%, which not only enhances accuracy but also provides customers with faster, more cost-effective solutions, facilitating support for complex applications.
- Flexible Workflow: The upcoming staggered starts and new flow cells will expand the application range of the NovaSeq X, allowing more applications to run on a single instrument, further enhancing customer experience and satisfaction.
- Raising Industry Standards: Illumina's updates will set a new industry standard for oncology and rare disease research, expected to improve human health, drive treatment breakthroughs, and develop diagnostic models, further solidifying its leadership position in genomics.
See More
Illumina Unveils Major Updates to NovaSeq X System
- Output Increase: Illumina announces a 40% increase in output for the NovaSeq X system, reaching 35 billion reads, which will enable larger and more complex studies on the same instrument, further advancing precision medicine.
- Quality and Speed Innovations: The new technology will achieve a Q70 quality score for the first time and reduce turnaround times by 30% on WGS workflows, enhancing data accuracy and accelerating progress in clinical and research applications.
- Enhanced Flexibility: By introducing new flow cells and staggered starts, Illumina optimizes flow cell usage, increasing read volumes for single-cell and proteomics applications, thereby enhancing instrument flexibility and throughput.
- Market Impact: These updates will benefit the global user base of 890 NovaSeq X systems, further solidifying Illumina's leadership in genomics and providing higher-quality data support for cancer and rare disease research.
See More
Illumina Management to Participate in Investor Conference
- Investor Conference Schedule: Illumina will hold an investor conference at 12:10 PM PT (3:10 PM ET), where management will participate in discussions, likely attracting investor interest and enhancing company transparency.
- Webcast Availability: The conference will be accessible via a live webcast on Illumina's website, allowing global investors to participate in real-time and obtain the latest information, with a replay available for at least 30 days post-event.
- Company Background: Illumina focuses on innovation in genomics and has established itself as a global leader in DNA sequencing and array technologies, with products widely used in life sciences, oncology, reproductive health, and other emerging fields, showcasing its strong influence in the biotech industry.
- Multi-Channel Engagement: Illumina encourages investors to connect through its social media platforms (such as X, Facebook, LinkedIn, etc.), enhancing interaction with investors and increasing brand awareness and market impact.
See More
Illumina Launches TruPath Genome Technology Setting New Standards
- Technological Innovation: Illumina's TruPath Genome technology offers a cost-effective whole genome analysis solution at a list price of $395, providing at least 30x coverage depth, making clinical research more feasible and economical.
- High Throughput: The TruPath Genome technology generates 16 whole genomes per day with only 10 minutes of hands-on time, nearly doubling the throughput of competing long-read methods, significantly enhancing the efficiency of genomic research.
- Accuracy Enhancement: This technology achieves up to 98% complete gene phasing through advanced flow cell library preparation and DRAGEN algorithms, enabling comprehensive variant detection in difficult genomic regions, thus advancing rare disease research.
- Market Adoption: Over 30 early access customers, including GeneDx and Baylor College of Medicine, have piloted the TruPath Genome technology in the past 16 months, indicating strong market interest and application potential for this innovative solution.
See More
Illumina Launches TruPath Genome Technology for Genetic Insights
- Technological Innovation: Illumina's launch of TruPath™ Genome technology offers up to 30x coverage, significantly enhancing the detection capabilities for rare genetic diseases, which is expected to drive advancements in genomic research.
- Streamlined Workflow: The technology simplifies the sample-to-sequencer workflow, generating 16 whole genomes in just 10 minutes of hands-on time, nearly doubling the throughput of competitors, thereby reducing operational complexity in laboratories.
- Clinical Application Potential: Broad Clinical Labs is among the first to adopt TruPath, which is expected to advance rare disease research and improve the ability to analyze complex genetic variants through this technology.
- Positive Market Response: Over 30 early access customers have piloted the technology in the past 16 months, indicating strong market demand and suggesting that TruPath will lead a new trend in the field of genomics.
See More
Opportunities in Healthcare Stocks Amid Market Volatility
- Market Seasonality Insight: Historical data over the past decade shows that the S&P 500 typically experiences weakness in February, which explains the current market volatility while indicating the rotation of capital across sectors.
- Capital Flow Trends: Institutional money is actively moving out of high-beta tech and consumer discretionary sectors, seeking refuge in more defensive areas such as consumer staples, utilities, and healthcare, reflecting a preference for stable investments in uncertain times.
- Healthcare Sector Performance: The healthcare sector, represented by the State Street Health Care Select Sector SPDR ETF (XLV), is firmly entering the leading quadrant, indicating that selective bullish setups are available even amidst broader market turbulence.
- Illumina Trade Strategy: For Illumina Inc. (ILMN), a bull call spread between $120 and $125 allows investors to enter at a cost of $250 per contract, targeting a potential profit of $250, showcasing flexibility and risk management in the current market environment.
See More
Illumina Unveils NovaSeq X System Innovation Roadmap
- Output Increase: Illumina announces a 40% increase in output for the NovaSeq X system, reaching 35 billion reads, which is expected to significantly enhance daily sequencing productivity, thereby meeting customer demands for high-throughput sequencing and advancing precision medicine.
- Quality and Speed Innovations: The new technology will achieve a Q70 quality score for the first time and increase sequencing speed by 30%, which not only enhances accuracy but also provides customers with faster, more cost-effective solutions, facilitating support for complex applications.
- Flexible Workflow: The upcoming staggered starts and new flow cells will expand the application range of the NovaSeq X, allowing more applications to run on a single instrument, further enhancing customer experience and satisfaction.
- Raising Industry Standards: Illumina's updates will set a new industry standard for oncology and rare disease research, expected to improve human health, drive treatment breakthroughs, and develop diagnostic models, further solidifying its leadership position in genomics.
See More
Illumina Unveils Major Updates to NovaSeq X System
- Output Increase: Illumina announces a 40% increase in output for the NovaSeq X system, reaching 35 billion reads, which will enable larger and more complex studies on the same instrument, further advancing precision medicine.
- Quality and Speed Innovations: The new technology will achieve a Q70 quality score for the first time and reduce turnaround times by 30% on WGS workflows, enhancing data accuracy and accelerating progress in clinical and research applications.
- Enhanced Flexibility: By introducing new flow cells and staggered starts, Illumina optimizes flow cell usage, increasing read volumes for single-cell and proteomics applications, thereby enhancing instrument flexibility and throughput.
- Market Impact: These updates will benefit the global user base of 890 NovaSeq X systems, further solidifying Illumina's leadership in genomics and providing higher-quality data support for cancer and rare disease research.
See More
Illumina Management to Participate in Investor Conference
- Investor Conference Schedule: Illumina will hold an investor conference at 12:10 PM PT (3:10 PM ET), where management will participate in discussions, likely attracting investor interest and enhancing company transparency.
- Webcast Availability: The conference will be accessible via a live webcast on Illumina's website, allowing global investors to participate in real-time and obtain the latest information, with a replay available for at least 30 days post-event.
- Company Background: Illumina focuses on innovation in genomics and has established itself as a global leader in DNA sequencing and array technologies, with products widely used in life sciences, oncology, reproductive health, and other emerging fields, showcasing its strong influence in the biotech industry.
- Multi-Channel Engagement: Illumina encourages investors to connect through its social media platforms (such as X, Facebook, LinkedIn, etc.), enhancing interaction with investors and increasing brand awareness and market impact.
See More
